Migraine drug showdown: which works better for patients?
NCT ID NCT06680206
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at survey responses from over 1,300 people with migraine in the U.S. to compare those taking rimegepant (Nurtec) with those taking triptans. Researchers examined treatment satisfaction, quality of life, work productivity, and disability. The goal was to see if one group reported better outcomes than the other.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rimegepant and triptans
What this could lead to
If the results show rimegepant users report better satisfaction, quality of life, or less disability, it could help doctors and patients choose between migraine treatments.
What could go wrong
This is an observational survey, not a controlled trial, so it can only show links, not cause and effect. Differences between groups may be due to other factors, not the drugs themselves.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
New York, New York, 10001, United States